CytoMed Therapeutics (GDTC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GDTC CytoMed Therapeutics

Watchlist

2.200
-0.010-0.46%

Close Nov 21 16:00 ET

25.39MMarket Cap-10837P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cytomed Therapeutics Announces First Patient Dosed in ANGELICA Trial
TipRanksNov 20 07:26 ET
Express News | CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological...
BenzingaNov 20 07:12 ET
Osteopore Teams Up With CytoMed Therapeutics for Cellular Product Development; Shares Up 3%
MT NewswiresOct 16 23:20 ET
CytoMed Therapeutics Price Target Maintained With a $5.00/Share by Benchmark
Dow JonesOct 10 09:29 ET · Ratings
CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
BenzingaOct 3 07:34 ET
Earnings Preview: GDTC to Report Financial Results Pre-market on October 08
Moomoo NewsOct 2 21:00 ET

Comments

Jaguar8

Nov 20 06:02

NEWS

$CytoMed Therapeutics (GDTC.US)$
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited(NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnes...

Jaguar8

Oct 7 06:03

NEWS

$CytoMed Therapeutics (GDTC.US)$
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to dev...

Trytosaveabit

Oct 3 06:40

Update

$CytoMed Therapeutics (GDTC.US)$ CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
Benzinga· 4 mins ago
The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units, and (iii) two freehold real estate properties totalling 189 square metres in which the operation is situated.This acqui...